The NHS has approved the first daily pill, relugolix combination therapy, to treat endometriosis symptoms in England, offering an alternative to injectable options and costing £72 for a 28-day round. While the pill is a positive step, it may only help about 1,000 women out of 1.5 million affected in the UK, highlighting the chronic underfunding and lack of prioritization of women’s health care. Despite the progress, issues such as delays in diagnosis and lack of specialist care continue to persist, underscoring the need for further innovations and investments in women’s health.
Full Article
Loading PerspectiveSplit analysis...
